购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • PD-1/PD-L1
    (2)
  • Others
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 5日内发货
    (1)
  • 35日内发货
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "pd 1/pd l1 in 10"的结果
筛选
搜索结果
TargetMol产品目录中 "

pd 1/pd l1 in 10

"的结果
  • 抑制剂&激动剂
    3
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    1
    TargetMol | Recombinant_Protein
  • PD-1/PD-L1-IN-10
    T96162487550-41-2
    PD-1 PD-L1-IN-10 是一种口服有效的PD-1 PD-L1抑制剂 (IC50值为2.7 nM),显示出抗肿瘤活性。
    • ¥ 456
    In stock
    规格
    数量
  • INCB086550
    PD-1 PD-L1-IN-8
    T368992230911-59-6
    INCB086550 (PD-1 PD-L1-IN-8) (example 24) 是 PD-1 PD-L1 的抑制剂,其IC50 值为 <= 10 nM。
    • ¥ 1260
    In stock
    规格
    数量
  • Diprovocim-1
    T377222170867-89-5
    Diprovocim-1 is an agonist of the toll-like receptor 1/2 heterodimer.1It induces TNF-α release in THP-1 cells (EC50= 110 pM), an effect that can be inhibited by anti-TLR1 or anti-TLR2 antibodies. Diprovocim-1 (10 mg/kg) increases the production of ovalbumin-specific IgG1 in wild-type, but notTLR2-/-, mice sensitized to ovalbumin.2It also enhances anti-PD-L1 antibody-induced activation of cytotoxic T lymphocytes, reduction of tumor growth, and increases in survival in a B16/F10 murine melanoma model. 1.Morin, M.D., Wang, Y., Jones, B.T., et al.Diprovocims: A new and exceptionally potent class of toll-like receptor agonistsJ. Am. Chem. Soc.140(43)14440-14454(2018) 2.Wang, Y., Su, L., Morin, M.D., et al.Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in miceProc. Natl. Acad. Sci. U.S.A.115(37)E8698-E8706(2018)
    • 待估
    35日内发货
    规格
    数量